+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Augmentation strategies in clozapine-resistant schizophrenia



Augmentation strategies in clozapine-resistant schizophrenia



Cns Drugs 19(10): 843-872



The introduction of antipsychotics in the 1950s revolutionised the treatment of schizophrenia, but it soon became apparent that a substantial number of patients demonstrated a suboptimal response to these antipsychotics. Clozapine proved to be beneficial in patients whose symptoms were treatment resistant, but it too had limitations, with as many as 40-70% of those treated with clozapine demonstrating inadequate response to this drug as well. The availability of other 'atypical' antipsychotics offers options, but clozapine appears to remain the most effective option in treatment-resistant schizophrenia. This, of course, raises the question of what to do when clozapine is only partially effective. To address the issue of treatment in patients who have demonstrated a suboptimal response to clozapine, efforts have focused on a variety of augmentation strategies, including numerous medications and electroconvulsive therapy. The current body of evidence consists largely of data from smaller open trials and case series/reports, although data from a limited number of controlled studies are now available. Not surprisingly, the evidence drawn from the former is more supportive of augmentation strategies, although the controlled trials are not without positive findings. The available information is certainly not so overwhelming as to endorse any single augmentation approach. Indeed, it argues for more controlled data and cautions us regarding the cost-benefit ratio in adopting this strategy. Over and above the added adverse effects of another treatment, there is evidence to indicate that actual clinical worsening can occur. Without compelling evidence, clinicians must resort to guiding principles. The potential benefits of augmentation cannot be ruled out, but it should be approached with caution and in a systematic fashion. Factors compromising clozapine response should first be ruled out, and any augmentation trials should be guided by existing evidence and a treatment plan that incorporates a clear understanding of target symptoms. A means of evaluating outcome effectively needs to be in place, and the trial should be circumscribed to prevent needless polypharmacy. A priori, an endpoint needs to be established and the trial discontinued unless results firmly support added benefits.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048338495

Download citation: RISBibTeXText

PMID: 16185094

DOI: 10.2165/00023210-200519100-00004


Related references

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research 105: 23-32, 2018

Fluvoxamine augmentation for clozapine-resistant schizophrenia. American Journal of Psychiatry 152(7): 1098, 1995

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 29(1): 28-33, 2006

Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia. Psychiatry Investigation 14(1): 58-62, 2017

Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. Journal of Psychopharmacology 28(7): 707-708, 2014

Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34(4): 724-725, 2010

Is electroconvulsive therapy effective as augmentation in clozapine-resistant schizophrenia?. Medwave 16(Suppl5): E6577, 2016

Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a French sample. European Neuropsychopharmacology 26: S541-S542, 2016

Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biological Psychiatry 40(7): 671-674, 1996

Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review. Case Reports in Psychiatry 2015: 678040, 2015

Clozapine augmentation with another antipsychotic for treatment-resistant schizophrenia: a meta-analysis. 2007

Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clinical Drug Investigation 26(3): 117-124, 2006

Augmentation of clozapine with paliperidone in treatment-resistant schizophrenia-A case series. Acta Neuropsychiatrica 23(1): 51-53, 2011

Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian and new Zealand Journal of Psychiatry 52(8): 751-767, 2018